NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Eliem Therapeutics, Inc. (ELYM) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 2 recommend buying, 2 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
